Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 13

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 13
---
 -6.9% AER, -3.9% CER). The decrease was primarily attributable to a decrease in revenue in Neuroscience and unfavorable foreign exchange rates. The decrease in Neuroscience revenue was largely attributable to the continued impact from generic erosion of VYVANSE in the U.S. Takeda’s Growth and Launch Products * totaled JPY 1,143.0 billion (JPY +16.0 billion and +1.4% AER, +5.3% CER).

* Takeda’s Growth and Launch Products

GI: ENTYVIO, EOHILIA

Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA

PDT: Immunoglobulin products including GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU,

Albumin products including HUMAN ALBUMIN and FLEXBUMIN

Oncology: ALUNBRIG, FRUZAQLA

Vaccines: QDENGA

#### Core Operating Profit
Core Operating Profit was JPY 639.2 billion (JPY -80.7 billion and -11.2% AER, -8.8% CER ) . The components of Core Operating Profit are as below:

|                                                          |     |           |     |            |         |     |           |     |          |         |     |     |     |          |        |     |       |   |     |     |      | Billion JPY or percentage |
|                                                          |     | FY2024 H1 |     |            |         |     | FY2025 H1 |     |          |         |     | AER |     |          |        |     |       |   | CER |     |      |                           |
|                                                          |     |           |     | JPY Change |         |     |           |     | % Change |         |     |     |     | % Change |        |     |       |   |     |     |      |                           |
| Core revenue                                             |     |           |     |            | 2,384.0 |     |           |     |          | 2,219.5 |     |     |     |          | -164.5 |     |  -6.9 | % |     |     | -3.9 | %                         |
| Core cost of sales                                       |     |           |     |            |  -